What You Should Expect From PF-01367338?

Матеріал з HistoryPedia
Версія від 12:00, 13 червня 2017, створена Drawer9parade (обговореннявнесок) (Створена сторінка: In another study, de [http://www.selleckchem.com/products/AG-014699.html PF-01367338 concentration] Lissovoy et al14 used mathematical modelling and computer si...)

(різн.) ← Попередня версія • Поточна версія (різн.) • Новіша версія → (різн.)
Перейти до: навігація, пошук

In another study, de PF-01367338 concentration Lissovoy et al14 used mathematical modelling and computer simulation to estimate the incremental cost per quality-adjusted life-year (QALY) for identical cohorts of children treated with ITB or alternative therapy over a 5-year time horizon. The incremental cost-effectiveness ratio was calculated to be $42?000 per QALY (approximately ?26?588), a figure considered as cost-effective, considering the willingness-to-pay threshold in the UK of between ?20?000 and ?30?000 per QALY. A systematic review evaluating the effect of continuous ITB infusion on function and quality of life in patients with severe spasticity concluded that ITB has a cost per QALY in the region of ?6900�C?12?800.18 This study suggests that despite the available evidence on effectiveness and cost-effectiveness, and although NHS England has issued a policy statement on ITB, there are still many patients who have not been able to access this therapy. We believe this to be related to the complexity of the set-up required to deliver the therapy and the need for interaction between a number of specialties, including neurosurgery, pain medicine, neurorehabilitation and spinal injuries, all of which may not be present on the same hospital site. The creation of specialist centres will and should overcome this problem in the future, although estimating the duration for the impact of specialised centres is difficult at this point. In comparison with other Western European countries, the UK is one of the lowest providers of ITB therapy. However, the data are available for other European countries for only 1?year, and therefore we cannot comment on trends. There is also a considerable variation in provision of services among various CCGs. The number of implants performed in the North of England commissioning region was 148 compared with 62 and 70 in the Midlands and South of England commissioning regions during the years 2012/2013. The number of implants cannot be explained based on population factors; the population figures are much higher for the South (27,830,219) than the North (15,845,124) and Midlands (12,694,544). We can only speculate that the differences may relate to several factors including a number of high-volume implanting centres based in the North of England. In addition, the variations in commissioning between CCGs may be explained by the individual ITB commissioning policies of the CCG precursors (the Primary Care Trusts) with more permissive Primary Care Trust policies towards implant of ITB pumps in the North than in the South or Midlands. It has previously been observed that commissioning policies varied vastly between Primary Care Trusts in respect to SCS commissioning.